Kendric Cromer, a 12-year-old boy from Washington, became the first person with sickle cell disease to undergo a commercially approved gene therapy that may cure the condition. This groundbreaking treatment offers hope to the estimated 20,000 individuals in the U.S. with sickle cell disease. Kendric’s journey highlights the challenges patients face in accessing new treatments, with the potential for significantly improving their quality of life and enabling them to engage in everyday activities without the fear of triggering painful episodes.
First Patient Begins Newly Approved Sickle Cell Gene Therapy
< 1 min read
